Form 4: United Therapeutics Executive Exercises Stock Options and Sells Shares Under Pre-Arranged Plan

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., exercised stock options and simultaneously sold 11,000 shares of common stock for approximately $3.47 million under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp. (UTHR), engaged in transactions involving the company's common stock on May 29, 2025.
• He exercised stock options to acquire a total of 11,000 shares: 7,000 shares at an exercise price of $135.42 and 4,000 shares at an exercise price of $117.76.
• Concurrently, he sold all 11,000 shares acquired from the option exercises.
• The sales occurred at weighted average prices ranging from $311.14 to $317.1932 per share.
• The total proceeds from the sale of 11,000 shares are approximately $3,476,843.
• Following these transactions, Mr. Mahon beneficially owns 36,781 shares of common stock directly.
• He also retains 143,000 unexercised stock options with an exercise price of $135.42, exercisable from March 15, 2023, and expiring on March 15, 2027.
• All transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on December 24, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling based on non-public information. It represents a routine monetization of executive compensation.

Positives

• The exercise of stock options indicates that the options were 'in the money,' meaning the market price was significantly higher than the exercise price, allowing the executive to realize a substantial gain.
• The transactions were executed under a pre-arranged 10b5-1 plan, which suggests the sales were planned in advance and not based on immediate, non-public information.

Negatives

• The sale of 11,000 shares by a high-ranking executive, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing for an executive in the biotechnology and pharmaceutical industry, common for executives managing their personal equity holdings and compensation.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the pre-arranged nature of the sale under a 10b5-1 plan typically lessens concerns about its implications for company prospects.

Key Dates

Recommendation

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation, Paul A. Mahon, Biotechnology, Pharmaceuticals